ES2150546T3 - Compuestos de 6-(2-imidazolinilamino)quinoxalina utiles como agonistas de alfa-2-adrenoceptores. - Google Patents

Compuestos de 6-(2-imidazolinilamino)quinoxalina utiles como agonistas de alfa-2-adrenoceptores.

Info

Publication number
ES2150546T3
ES2150546T3 ES95904326T ES95904326T ES2150546T3 ES 2150546 T3 ES2150546 T3 ES 2150546T3 ES 95904326 T ES95904326 T ES 95904326T ES 95904326 T ES95904326 T ES 95904326T ES 2150546 T3 ES2150546 T3 ES 2150546T3
Authority
ES
Spain
Prior art keywords
sub
compounds
imidazolinylamine
quinoxaline
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95904326T
Other languages
English (en)
Spanish (es)
Inventor
Peter Julian Maurer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co
Application granted granted Critical
Publication of ES2150546T3 publication Critical patent/ES2150546T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES95904326T 1993-12-17 1994-12-15 Compuestos de 6-(2-imidazolinilamino)quinoxalina utiles como agonistas de alfa-2-adrenoceptores. Expired - Lifetime ES2150546T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16978593A 1993-12-17 1993-12-17
PCT/US1994/014291 WO1995016449A1 (en) 1993-12-17 1994-12-15 6-(2-imidazolinylamino)quinoxaline compounds useful as alpha-2 adrenoceptor agonists

Publications (1)

Publication Number Publication Date
ES2150546T3 true ES2150546T3 (es) 2000-12-01

Family

ID=22617165

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95904326T Expired - Lifetime ES2150546T3 (es) 1993-12-17 1994-12-15 Compuestos de 6-(2-imidazolinilamino)quinoxalina utiles como agonistas de alfa-2-adrenoceptores.

Country Status (22)

Country Link
US (1) US5834470A (enExample)
EP (1) EP0735877B1 (enExample)
JP (1) JPH09506622A (enExample)
CN (1) CN1137755A (enExample)
AT (1) ATE194771T1 (enExample)
AU (1) AU701233B2 (enExample)
BR (1) BR9408342A (enExample)
CA (1) CA2179006A1 (enExample)
CZ (1) CZ175496A3 (enExample)
DE (1) DE69425334T2 (enExample)
DK (1) DK0735877T3 (enExample)
ES (1) ES2150546T3 (enExample)
FI (1) FI962493L (enExample)
GR (1) GR3034497T3 (enExample)
HU (1) HUT76283A (enExample)
NO (1) NO962538L (enExample)
PE (1) PE38195A1 (enExample)
PT (1) PT735877E (enExample)
SG (1) SG44628A1 (enExample)
SK (1) SK77396A3 (enExample)
TW (1) TW318141B (enExample)
WO (1) WO1995016449A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
US5856329A (en) † 1995-06-28 1999-01-05 Allergan Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury
US6194415B1 (en) 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
BR9713536A (pt) * 1996-11-25 2000-11-07 Procter & Gamble Compostos heterocìclicos de guanidinila úteis como agonistas de adrenoceptores alfa-2
JP2001506599A (ja) * 1996-11-25 2001-05-22 ザ プロクター アンド ギャンブル カンパニー アルファ−２アドレナリン受容体アゴニストとして有効な２−イミダゾリニルアミノインダゾール化合物
US6329369B1 (en) 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
US6841684B2 (en) 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
AU1319200A (en) * 1998-10-20 2000-05-08 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
US20030087962A1 (en) 1998-10-20 2003-05-08 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
US7973068B2 (en) 1998-10-20 2011-07-05 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
EP1365811A2 (en) * 2000-07-14 2003-12-03 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20050026924A1 (en) * 2000-07-14 2005-02-03 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US8858961B2 (en) 2000-07-14 2014-10-14 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20020198209A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US7030149B2 (en) 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
CA2505836C (en) * 2004-05-06 2013-08-27 Alcon Inc. Topical brimonidine tartrate formulations that lack chlorine dioxide
US8067433B2 (en) 2005-11-09 2011-11-29 Zalicus Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
US20130115320A1 (en) 2007-03-30 2013-05-09 Dynova Laboratories, Inc. Therapeutic agent for intranasal administration and method of making and using same
US20080241290A1 (en) * 2007-03-30 2008-10-02 Wayne Jeffrey Perry Sinus relief composition and method of producing the same
US20080242741A1 (en) * 2007-03-30 2008-10-02 Wayne Jeffrey Perry Intranasal drug delivery system
US20090069446A1 (en) * 2007-09-06 2009-03-12 Wayne Jeffrey Perry Dendritic salt therapeutic agent delivery system
US20090069433A1 (en) * 2007-09-10 2009-03-12 Wayne Jeffrey Perry Nasal rinse additive
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
RU2014106364A (ru) * 2011-07-25 2015-08-27 Аллерган, Инк. Производные n-(имидазолидин-2-илидин)хинолина как модуляторы адренергических рецепторов альфа-2

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795970A (fr) * 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4029792A (en) * 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
US4036976A (en) * 1973-04-05 1977-07-19 Sandoz, Inc. Substituted imidazolinylamino-indazoles
US4217356A (en) * 1975-08-22 1980-08-12 Sandoz Ltd. 2-Imidazolinylamino-2,1,3-benzothiadiazoles
US4398028A (en) * 1977-01-14 1983-08-09 Sandoz Ltd. Bicyclic heterocyclic amino derivatives
EP0025269B1 (en) * 1979-08-23 1985-11-13 Beecham Group Plc Anti-diarrhoea veterinary composition
WO1982000824A1 (en) * 1980-09-05 1982-03-18 Geissmann F 1h and 2h indazol derivatives and medicaments containing them
FR2521140A1 (fr) * 1982-02-05 1983-08-12 Synthelabo Derives d'imidazolidine, leur preparation et leur application en therapeutique
FR2638356A1 (fr) * 1988-10-28 1990-05-04 Anben Nouveaux derives de la 2-arylimino-imidazolidine pour diminuer la pression intra-oculaire et traiter le glaucome
US5180721A (en) * 1989-05-22 1993-01-19 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5281591A (en) * 1989-05-22 1994-01-25 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5231096A (en) * 1989-10-12 1993-07-27 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5077292A (en) * 1989-10-12 1991-12-31 Allergan, Inc. (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same
US5021416A (en) * 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5096916A (en) * 1990-05-07 1992-03-17 Aegis Technology, Inc. Treatment of chronic obstructive pulmonary disease (copd) by inhalation of an imidazoline
US5091528A (en) * 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents

Also Published As

Publication number Publication date
SK77396A3 (en) 1997-01-08
HU9601662D0 (en) 1996-08-28
CN1137755A (zh) 1996-12-11
NO962538L (no) 1996-08-13
PT735877E (pt) 2000-12-29
GR3034497T3 (en) 2000-12-29
DK0735877T3 (da) 2000-11-06
JPH09506622A (ja) 1997-06-30
CZ175496A3 (en) 1996-11-13
AU701233B2 (en) 1999-01-21
HUT76283A (en) 1997-07-28
PE38195A1 (es) 1995-11-27
NO962538D0 (no) 1996-06-14
TW318141B (enExample) 1997-10-21
EP0735877B1 (en) 2000-07-19
BR9408342A (pt) 1997-08-19
US5834470A (en) 1998-11-10
SG44628A1 (en) 1997-12-19
EP0735877A1 (en) 1996-10-09
ATE194771T1 (de) 2000-08-15
FI962493A0 (fi) 1996-06-14
FI962493A7 (fi) 1996-07-26
DE69425334T2 (de) 2001-02-08
DE69425334D1 (de) 2000-08-24
FI962493L (fi) 1996-07-26
WO1995016449A1 (en) 1995-06-22
CA2179006A1 (en) 1995-06-22
AU1306195A (en) 1995-07-03

Similar Documents

Publication Publication Date Title
DK0735877T3 (da) 6-(2-imidazolinylamino)quinoxalinforbindelser, der er egnede som alfa-2-adrenoceptoragonister.
ES2189824T3 (es) Antagonistas no peptidicos del receptor de taquiquininas.
ES2158076T3 (es) Compuestos 7-(2-imidazolinilamino)quinolinicos utiles como agonistas de alfa-2 adrenoceptores.
ES2178676T3 (es) Compuestos de pirimidina substituidos y su empleo.
CO5060522A1 (es) Administracion de un agente activo en aerosol
NO912758D0 (no) Anvendelse av det virksomme stoffet flupirtin for bekjempelse av muskelspenninger.
ES2178048T3 (es) Uso de rifaximina como medicamento para el tratamiento de diarrea por criptosporidiosis.
ES2125377T3 (es) Azaheterociclicos triciclicos n-acilatados utiles como antagonistas de vasopresina.
ES2136723T3 (es) Utilizacion de n-aril-metilen-etilen-diamino-triacetatos, n-aril-metilen-imino-diacetatos o n,n'-diaril-metilen-etilen-diamino-acetatos contra el estres oxidante.
ES2037681T3 (es) Procedimiento para preparar nuevos estirilpirazoles, isoxazoles y analogos de los mismos que tienen actividad como inhibidores de 5-lipoxigenasa.
ES2196361T3 (es) Combinaciones terapeuticas de antagonistas de rar y agonistas de rxr.
ES2063146T3 (es) Composiciones farmaceuticas que contienen acido n-(3,4-dimetoxicinamoil)-antranilico.
ES2032390T3 (es) Composicion antihipertensiva ocular para uso topico. (reserva del art. 167.2 cpe).
ZA947957B (en) Substituted 1-naphthyl-3-pyrazolecarboxamides which are active in neurotensin their preparation and pharmaceutical compositions containing them
MY121054A (en) Calcilytic compounds as calcium receptor antagonists.
ES2146307T3 (es) Compuestos de 6-(2-imidazolinilamino)quinolina utiles como agonistas de adrenoceptores 2-alfa.
EA200200562A1 (ru) Антагонисты аденозиновых рецепторов и способы их получения и использования
ES2116411T3 (es) La sal sulfato de un triazol sustituido, composiciones farmaceuticas de la misma y su uso en terapia
ES2116634T3 (es) Nuevo empleo de 1alfa-fluoro-25-hidroxi-16-en-23-in-colecalciferol.
EP0240907A3 (en) Use of trans-4-û(2-amino-3,5-dibromobenzyl)amino¨cyclohexanol
HU0003408D0 (en) Petrolatum-based nose ointment
YU40398A (sh) Kompozicija nazalnog spreja za davanje sredstva za lečenje odloženog napada emezisa
ES2059260B1 (es) Procedimiento de preparacion de comprimidos conteniendo diclofenaco; dispersables en agua.
ES2062261T3 (es) Procedimiento para la preparacion de bromuros de alquilo ampliamente fluorados.
MX9302818A (es) Agente para incrementar somatostatina o para inhibir la reduccion de somatostatina.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 735877

Country of ref document: ES